The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1594
ISSUE1594
March 23, 2020
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Download PDF: US English
Med Lett Drugs Ther. 2020 Mar 23;62(1594):48
Disclosures
Principal Faculty- Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
- Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
- Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
- F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
- Discuss how drospirenone (Slynd) compares to norethindrone as a progestin-only oral contraceptive.
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and antimineralocorticoid activity that could cause hyperkalemia. We should have added that concurrent use of drospirenone with other drugs that increase potassium levels, such as the anti-androgen aldosterone receptor antagonist spironolactone (Aldactone, and generics), which is often used off-label for treatment of acne, can increase the risk of hyperkalemia.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article